Glioblastoma patients typically face about eight months of survival, a heartbreaking reality that has lingered for decades. However, there’s exciting news from researchers at Keck Medicine who have made a significant breakthrough by combining Tumour Treating Fields (TTFields) with immunotherapy, leading to a remarkable 70% extension in survival during clinical trials.
This elegant fusion of physics and biology operates like a finely-tuned orchestra: low-intensity electric fields disrupt cancer cell division while also drawing immune cells into the brain, which is a fortress usually protected from the body’s natural defences. This innovative approach transforms glioblastoma from an immunologically “cold” tumour into a target that’s ready for action.
For families navigating this challenging diagnosis, the implications go far beyond just statistics. Those valuable extra months mean the joy of witnessing graduations, celebrating anniversaries, and making lasting memories together. This breakthrough brings special hope for patients with inoperable tumours, who demonstrated even more robust responses, questioning the traditional belief in the necessity of surgery.
This advancement highlights biotechnology’s incredible power to rethink treatment strategies, turning the body’s own defence systems into true allies in the fight against some of the toughest adversaries we face at the cellular level.
Lambda Biologics’ Oncology Solutions: The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs). This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.
Cancer Associate Fibroblast (CAF) | Cytotoxic T cell | Tumor-Infiltrating Lymphocyte | Regulatory T cell | Macrophage
